RS56810B1 - Indolkarbonitrili kao selektivni modulatori androgen receptora - Google Patents

Indolkarbonitrili kao selektivni modulatori androgen receptora

Info

Publication number
RS56810B1
RS56810B1 RS20180119A RSP20180119A RS56810B1 RS 56810 B1 RS56810 B1 RS 56810B1 RS 20180119 A RS20180119 A RS 20180119A RS P20180119 A RSP20180119 A RS P20180119A RS 56810 B1 RS56810 B1 RS 56810B1
Authority
RS
Serbia
Prior art keywords
compound
trifluoromethyl
compounds
muscle
disease
Prior art date
Application number
RS20180119A
Other languages
English (en)
Serbian (sr)
Inventor
Philip Stewart Turnbull
Rodolfo Cadilla
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS56810(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of RS56810B1 publication Critical patent/RS56810B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
RS20180119A 2012-07-17 2013-07-15 Indolkarbonitrili kao selektivni modulatori androgen receptora RS56810B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261672455P 2012-07-17 2012-07-17
US201361748874P 2013-01-04 2013-01-04
PCT/IB2013/001530 WO2014013309A1 (en) 2012-07-17 2013-07-15 Indolecarbonitriles as selective androgen receptor modulators
EP13758975.0A EP2875013B1 (en) 2012-07-17 2013-07-15 Indolecarbonitriles as selective androgen receptor modulators

Publications (1)

Publication Number Publication Date
RS56810B1 true RS56810B1 (sr) 2018-04-30

Family

ID=49117887

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180119A RS56810B1 (sr) 2012-07-17 2013-07-15 Indolkarbonitrili kao selektivni modulatori androgen receptora

Country Status (39)

Country Link
US (5) US8957104B2 (enExample)
EP (1) EP2875013B1 (enExample)
JP (1) JP6106746B2 (enExample)
KR (1) KR102127939B1 (enExample)
CN (1) CN104619693B (enExample)
AR (1) AR091770A1 (enExample)
AU (1) AU2013291721B2 (enExample)
BR (1) BR112015000940B1 (enExample)
CA (1) CA2879104C (enExample)
CL (1) CL2015000119A1 (enExample)
CO (1) CO7240378A2 (enExample)
CR (1) CR20150008A (enExample)
CY (1) CY1120064T1 (enExample)
DK (1) DK2875013T3 (enExample)
DO (1) DOP2015000004A (enExample)
EA (1) EA026371B8 (enExample)
ES (1) ES2657912T3 (enExample)
HR (1) HRP20180061T1 (enExample)
HU (1) HUE036238T2 (enExample)
IL (1) IL236448A (enExample)
IN (1) IN2014KN02993A (enExample)
JO (1) JO3384B1 (enExample)
LT (1) LT2875013T (enExample)
ME (1) ME02996B (enExample)
MX (1) MX349943B (enExample)
MY (2) MY198512A (enExample)
NZ (1) NZ703129A (enExample)
PE (1) PE20150371A1 (enExample)
PH (1) PH12015500104B1 (enExample)
PL (1) PL2875013T3 (enExample)
PT (1) PT2875013T (enExample)
RS (1) RS56810B1 (enExample)
SG (1) SG11201408493WA (enExample)
SI (1) SI2875013T1 (enExample)
SM (1) SMT201800115T1 (enExample)
TW (1) TWI574946B (enExample)
UY (1) UY34911A (enExample)
WO (1) WO2014013309A1 (enExample)
ZA (1) ZA201500096B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
CN104619693B (zh) 2012-07-17 2019-08-13 葛兰素史克知识产权第二有限公司 作为选择性雄激素受体调节剂的吲哚腈类
WO2015110958A1 (en) * 2014-01-21 2015-07-30 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile
KR20190077607A (ko) * 2014-10-16 2019-07-03 지티엑스, 인코포레이티드 Sarm을 이용하는 비뇨기 장애의 치료 방법
CN105130872B (zh) * 2015-08-25 2018-01-30 江西师范大学 一种3位三氟甲基取代吲哚的制备方法
CN110437125B (zh) * 2019-09-06 2021-03-12 苏州旺山旺水生物医药有限公司 一种Tezacaftor中间体II的制备方法
WO2022204235A1 (en) * 2021-03-23 2022-09-29 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
CN115010574B (zh) * 2022-06-06 2024-01-05 爱斯特(成都)生物制药股份有限公司 1-溴-2-氯-4-氟-2碘苯的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID27280A (id) 1998-02-25 2001-03-22 Genetics Inst Inhibitor-inhibitor dari enzim-enzim fosfolipase
AU3951899A (en) * 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
ES2471240T3 (es) 2002-05-24 2014-06-25 Bayer Cropscience Ag Procedimiento de preparación de derivados de tioalquilamina
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
CN1960973A (zh) * 2004-03-30 2007-05-09 惠氏公司 作为去甲肾上腺素(ne)与血清素(5-h t)活性和单胺重摄取的调控剂以治疗血管舒缩症状(vms)的1-(1h-吲哚-1-基)-3-(4-甲基哌嗪-1-基)-1-苯基丙烷-2-醇衍生物和相关化合物
CA2564953A1 (en) 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
WO2005111028A1 (en) 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
ATE525354T1 (de) 2004-05-03 2011-10-15 Janssen Pharmaceutica Nv Benzofuranderivate als selektive androgenrezeptormodulatoren (sarms)
DE602005020280D1 (de) * 2004-06-01 2010-05-12 Hoffmann La Roche 3-amino-1-arylpropyl-indole als monoamin-wiederaufnahmehemmer
WO2007012953A2 (en) * 2005-07-29 2007-02-01 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2007108936A2 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
CN101426778A (zh) * 2006-03-15 2009-05-06 惠氏公司 作为组胺-3拮抗剂的n-经取代-氮杂环基胺
WO2008042571A2 (en) 2006-09-29 2008-04-10 Smithkline Beecham Corporation Substituted indole compounds
RS53382B (sr) * 2008-08-20 2014-10-31 Zoetis Llc Jedinjenja pirol [2,3-d]pirimidina
US9095572B2 (en) 2009-01-09 2015-08-04 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2010118287A1 (en) * 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
AU2010308028A1 (en) * 2009-10-15 2012-04-19 Pfizer Inc. Pyrrolo[2,3-d] pyrimidine compounds
CA2782720A1 (en) * 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
RU2598842C2 (ru) * 2011-01-20 2016-09-27 Мерк Шарп Энд Домэ Корп. Антагонисты рецептора минералокортикоидов
JP6075736B2 (ja) * 2011-12-21 2017-02-08 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. ピロール−6員ヘテロアリール環誘導体、その合成法およびその医薬用途
CN104619693B (zh) * 2012-07-17 2019-08-13 葛兰素史克知识产权第二有限公司 作为选择性雄激素受体调节剂的吲哚腈类
WO2015110958A1 (en) * 2014-01-21 2015-07-30 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile

Also Published As

Publication number Publication date
DK2875013T3 (en) 2018-01-22
BR112015000940B1 (pt) 2022-05-17
CY1120064T1 (el) 2018-12-12
IL236448A0 (en) 2015-02-26
CL2015000119A1 (es) 2015-04-24
UY34911A (es) 2014-02-28
EA026371B1 (ru) 2017-03-31
EA026371B8 (ru) 2017-06-30
JP2015522603A (ja) 2015-08-06
PE20150371A1 (es) 2015-03-27
DOP2015000004A (es) 2015-03-15
US20200270210A1 (en) 2020-08-27
IN2014KN02993A (enExample) 2015-05-08
HK1208867A1 (en) 2016-03-18
MY198512A (en) 2023-09-01
CO7240378A2 (es) 2015-04-17
US20140024694A1 (en) 2014-01-23
US20150080449A1 (en) 2015-03-19
IL236448A (en) 2016-10-31
MY173845A (en) 2020-02-24
EP2875013B1 (en) 2017-11-29
AU2013291721A1 (en) 2015-02-26
AU2013291721B2 (en) 2016-02-25
LT2875013T (lt) 2018-02-26
HUE036238T2 (hu) 2018-06-28
US9533948B2 (en) 2017-01-03
BR112015000940A2 (pt) 2017-06-27
EP2875013A1 (en) 2015-05-27
MX2015000825A (es) 2015-07-17
KR20150032333A (ko) 2015-03-25
PH12015500104A1 (en) 2015-03-02
HRP20180061T1 (hr) 2018-02-23
US20190127326A1 (en) 2019-05-02
US8957104B2 (en) 2015-02-17
US20170073309A1 (en) 2017-03-16
AR091770A1 (es) 2015-02-25
ES2657912T3 (es) 2018-03-07
US10710963B2 (en) 2020-07-14
JO3384B1 (ar) 2019-03-13
PT2875013T (pt) 2018-02-28
PH12015500104B1 (en) 2015-03-02
PL2875013T3 (pl) 2018-06-29
CR20150008A (es) 2015-03-09
KR102127939B1 (ko) 2020-06-29
NZ703129A (en) 2017-06-30
TW201416349A (zh) 2014-05-01
SMT201800115T1 (it) 2018-03-08
US10196353B2 (en) 2019-02-05
MX349943B (es) 2017-08-21
ME02996B (me) 2018-10-20
ZA201500096B (en) 2017-07-26
CN104619693B (zh) 2019-08-13
SI2875013T1 (en) 2018-03-30
CA2879104A1 (en) 2014-01-23
SG11201408493WA (en) 2015-02-27
CN104619693A (zh) 2015-05-13
US11299457B2 (en) 2022-04-12
JP6106746B2 (ja) 2017-04-05
EA201492237A1 (ru) 2015-06-30
CA2879104C (en) 2020-08-25
WO2014013309A1 (en) 2014-01-23
TWI574946B (zh) 2017-03-21

Similar Documents

Publication Publication Date Title
US11299457B2 (en) Chemical compounds
JP5603327B2 (ja) テトラヒドロシクロペンタ[b]インドールアンドロゲン受容体調節物質
JP6824954B2 (ja) mIDH1阻害剤としての5−ヒドロキシアルキルベンズイミダゾール
US11001556B2 (en) Crystalline forms
ES2461520T3 (es) Modulador de receptores de andrógenos y sus usos
HK1208867B (en) Indolecarbonitriles as selective androgen receptor modulators
UA112898C2 (uk) Індолкарбонітрили як селективні модулятори андрогенного рецептора